Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1165-1172

  Pachón Ibáñez, María E ^a   Docobo Pérez, Fernando ^a   López Rojas, Rafael ^a   Domínguez Herrera, Juan ^a   Jiménez Mejias, Manuel E ^a   García Curiel, Andrés ^a   Pichardo, Cristina ^a   Jiménez, Luis ^a   Pachón, Jerónimo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; IMIPENEM; RIFAMPICIN; SULBACTAM;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BLOOD CULTURE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL INFECTION; FEMALE; IN VITRO STUDY; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIPENEM; MENINGITIS, BACTERIAL; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; RABBITS; RIFAMPIN; SULBACTAM; TREATMENT OUTCOME;

EID: 77149153364     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00367-09     Document Type: Article

References (38)

1. Afzal-Shah, M., and D. M. Livermore. 1998. Worldwide emergence of carbapenem-resistant Acinetobacter spp. J. Antimicrob. Chemother. 41:576-577.
2. Alvarez-Lerma, F., M. Palomar, P. Olaechea, J. J. Otal, J. Insausti, and E. Cerda. 2007. National Study of Control of Nosocomial Infection in Intensive Care Units. Evolutive report of the years 2003-2005. Med. Intensiva 31:6-17. [In Spanish.]
3. Amsden, G. W. 2005. Tables of antimicrobial agent pharmacology, p. 635-700. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 6th ed., vol. 1. Elsevier Churchill Livingstone, Philadelphia, PA.
4. Bassetti, M., E. Repetto, E. Righi, S. Boni, M. Diverio, M. P. Molinari, M. Mussap, S. Artioli, F. Ansaldi, P. Durando, G. Orengo, F. Bobbio Pallavicini, and C. Viscoli. 2008. Colistin and rifampicin in the treatment of multidrugresistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 61: 417-420.
5. Bergogne-Berezin, E., and K. J. Towner. 1996. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9:148-165.
6. Cisneros, J. M., M. J. Reyes, J. Pachon, B. Becerril, F. J. Caballero, J. L. Garcia-Garmendia, C. Ortiz, and A. R. Cobacho. 1996. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin. Infect. Dis. 22:1026-1032.
7. Clinical and Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents. CLSI document M26-A. CLSI, Wayne, PA.
8. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. CLSI document M100-S15. CLSI, Wayne, PA.
9. Comité de l'Antibiogramme de la Société Française de Microbiologie. 2006. Communiqué 2006. Comite de l'Antibiogramme de la Société Française de Microbiologie, Paris, France.
10. Dacey, R. G., and M. A. Sande. 1974. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob. Agents Chemother. 6:437-441.
11. Eliopoulos, G., and R. Moellering. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Williams and Wilkins, Baltimore, MD.
12. Falagas, M. E., and S. K. Kasiakou. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40:1333-1341.
13. Frimödt-Moller, N., M. W. Bentzon, and V. F. Thomsen. 1986. Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. J. Infect. Dis. 154:511-517.
14. Garnacho-Montero, J., J. L. García-Garmendia, A. Barrero-Almodovar, F. J. Jiménez-Jiménez, C. Pérez-Paredes, and C. Ortiz-Leyba. 2003. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit. Care Med. 31:2742-2751.
15. Garnacho-Montero, J., C. Ortiz-Leyba, F. J. Jimenez-Jimenez, A. E. Barrero-Almodovar, J. L. Garcia-Garmendia, I. M. Bernabeu-Wittel, S. L. Gallego-Lara, and J. Madrazo-Osuna. 2003. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin. Infect. Dis. 36:1111-1118.
16. Gaynes, R., and J. R. Edwards. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854.
17. Jimenez-Mejias, M. E., J. Pachon, B. Becerril, J. Palomino-Nicas, A. Rodriguez-Cobacho, and M. Revuelta. 1997. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin. Infect. Dis. 24:932-935.
18. Jimenez-Mejias, M. E., C. Pichardo-Guerrero, F. J. Marquez-Rivas, D. Martin-Lozano, T. Prados, and J. Pachon. 2002. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 21:212-214.
19. Klassen, M., and S. Edberg. 1996. Measurement of antibiotic in human body fluids: techniques and significance, p. 230-295. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Williams & Wilkins, Baltimore, MD.
20. Kucers, A., S. Crowe, M. L. Grayson, and J. Hoy. 1997. Polymixins, p. 667-675. In A. Kucers, S. Crowe, M. L. Grayson, and J. Hoy (ed.), The use of antibiotics. A clinical review of antibacterial, antifungal and antiviral drugs, 5th ed. Butterworth, Heinemann, Oxford, United Kingdom.
21. Levin, A. S., C. E. Levy, A. E. Manrique, E. A. Medeiros, and S. F. Costa. 2003. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int. J. Antimicrob. Agents 21: 58-62. 22. Martín-Lozano, D., J. M. Cisneros, B. Becerril, L. Cuberos, T. Prados, C. Ortiz-Leyba, E. Cañas, and J. Pachón. 2002. Comparison of a repetitive extragenic palindromic sequence-based PCR method and clinical and microbiological methods for determining strain sources in cases of nosocomial Acinetobacter baumannii bacteremia. J. Clin. Microbiol. 40:4571-4575.
22. Montero, A., J. Ariza, X. Corbella, A. Domenech, C. Cabellos, J. Ayats, F. Tubau, C. Ardanuy, and F. Gudiol. 2002. Efficacy of colistin versus betalactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 46:1946-1952.
23. Montero, A., J. Ariza, X. Corbella, A. Domenech, C. Cabellos, J. Ayats, F. Tubau, C. Borraz, and F. Gudiol. 2004. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J. Antimicrob. Chemother. 54:1085-1091.
24. Motaouakkil, S., B. Charra, A. Hachimi, H. Nejmi, A. Benslama, N. Elmdaghri, H. Belabbes, and M. Benbachir. 2006. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J. Infect. 53:274-278.
25. Ng, J., I. B. Gosbell, J. A. Kelly, M. J. Boyle, and J. K. Ferguson. 2006. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J. Antimicrob. Chemother. 58:1078-1081.
26. Pachón-Ibáñez, M. E., F. Fernandez-Cuenca, F. Docobo-Perez, J. Pachón, and A. Pascual. 2006. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J. Antimicrob. Chemother. 58:689-692.
27. Poirel, L., and P. Nordmann. 2006. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin. Microbiol. Infect. 12:826-836.
28. Rodriguez-Baño, J., J. M. Cisneros, F. Fernandez-Cuenca, A. Ribera, J. Vila, A. Pascual, L. Martinez-Martinez, G. Bou, and J. Pachon. 2004. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect. Control Hosp. Epidemiol. 25:819-824.
29. Rodriguez-Hernandez, M. J., L. Cuberos, C. Pichardo, F. J. Caballero, I. Moreno, M. E. Jimenez-Mejias, A. Garcia-Curiel, and J. Pachon. 2001. Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J. Antimicrob. Chemother. 47: 479-482.
30. Rodriguez-Hernandez, M. J., J. Pachon, C. Pichardo, L. Cuberos, J. Ibanez-Martinez, A. Garcia-Curiel, F. J. Caballero, I. Moreno, and M. E. Jimenez-Mejias. 2000. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J. Antimicrob. Chemother. 45:493-501.
31. Ruslami, R., H. M. Nijland, B. Alisjahbana, I. Parwati, R. van Crevel, and R. E. Aarnoutse. 2007. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 51:2546-2551.
32. Saballs, M., M. Pujol, F. Tubau, C. Pena, A. Montero, M. A. Dominguez, F. Gudiol, and J. Ariza. 2006. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 58:697-700.
33. Shumaker, R. C. 1986. PKCALC: a BASIC interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab. Rev. 17: 331-348.
34. Song, J. Y., H. J. Cheong, J. Lee, A. K. Sung, and W. J. Kim. 2009. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. International J. Antimicrob. Agents 33:33-39.
35. Taüber, M. G., H. Khayam-Bashi, and M. A. Sande. 1985. Effects of ampicillin and corticosteroids on brain water content, cerebrospinal fluid pressure, and cerebrospinal fluid lactate levels in experimental pneumococcal meningitis. J. Infect. Dis. 151:528-534.
36. Timurkaynak, F., F. Can, O. K. Azap, M. Demirbilek, H. Arslan, and S. O. Karaman. 2006. In vitro activities of nontraditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int. J. Antimicrob. Agents 27:224-228.
37. Wolff, M., M. L. Joly-Guillou, R. Farinotti, and C. Carbon. 1999. In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob. Agents Chemother. 43:1406-1411.
38. Wood, G. C., S. D. Hanes, M. A. Croce, T. C. Fabian, and B. A. Boucher. 2002. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin. Infect. Dis. 34:1425-1430.